Io in Humanitas
Unità
Unità Operativa di Oncologia Medica e Oncoematologia
Ruolo in Ospedale
Medico specialista in Oncologia Medica
Specializzazione
Oncologia Medica
Aree mediche di interesse
Neoplasia del tratto gastrointestinale e neoplasie neuroendocrine
Formazione
Laurea
Laurea in Medicina e Chirurgia
Anno di laurea: 2018
Università degli Studi di Catania
Specializzazione
Oncologia Medica
Anno di specializzazione: 2024
Università degli Studi di Verona
Pubblicazioni ed attività scientifica
- Organisational Challenges, Volumes Of Oncological Activity And Patients’ Perception During The Severe Acute Respiratory Syndrome Coronavirus 2 Epidemic. zuliani s, zampiva i, tregnago d, casali m, cavaliere a, fumagalli a, merler s, riva st, rossi a, zacchi f, zaninotto e, auriemma a, pavarana m, solda c, benini l, borghesani m, caldart a, casalino s, gaule m, kadrija d, mongillo m, pesoni c, biondani p, cingarlini s, fiorio e, melisi d, parolin v, tondulli l, belluomini l, zecchetto c, avesani b, biasi a, bovo c, dazzani e, dodi a, gelmini s, leta lc, lo cascio g, lombardo f, lucin e, martinelli ia, messineo l, moscarda v, pafumi s, reni a, sartori g, scaglione im, shoval y, sposito m, tacconelli e, trestini i, zambonin v, zanelli s, pilotto s, milella m. eur j cancer. 2020 aug;135:159-169. doi: 10.1016/j.ejca.2020.05.029
- Remarkable Response To Gemcitabine Rechallenge In Advanced Urothelial Carcinoma: A Case Report. merler s, pafumi s, zampiva i, zacchi f, manduca s, fantinel e, zivi a, milella m. anticancer drugs. 2022 nov 1;33(10):1171-1174. doi: 10.1097/cad.0000000000001387.
- Discordance Of Biomarker Expression Profile Between Primary Breast Cancer And Synchronous Axillary Lymph Node Metastasis In Preoperative Core Needle Biopsy. marletta s, giorlandino a, cavallo e, dello spedale venti m, leone g, tranchina mg, gullotti l, bonanno cl, spoto g, falzone g, tornabene i, trovato c, baron mm, di mauro g, falsaperna l, angelico g, pafumi s, rizzo a. diagnostics (basel) . 2024 jan 25;14(3):259. doi: 10.3390/diagnostics14030259
- Case Report: Strn3-Ntrk3 Fusion In Uterine Sarcoma With Spleen Metastasis: A New Variant In The Spectrum Of Ntrk-Rearranged Tumors. colombo p, buonamassa ga, giulianini a, hassan l, rudini n, rizzo a, cavallo e, carnaghi c, goudarzi s, mongiovi s, pafumi s, marletta s. case report: strn3-ntrk3 fusion in uterine sarcoma with spleen metastasis: a new variant in the spectrum of ntrk-rearranged tumors. front med (lausanne) . 2024 nov 8:11:1448491
RELATORE AI SEGUENTI CONGRESSI NAZIONALI ED INTERNAZIONALI: - le neoplasie genitourinarie, tra pratica clinica e innovazione 8/11/2022 brescia (italy)
- xlvii congresso nazionale aisp 07/09/2023 – 08/09/2023 bergamo (italy)
- congresso nazionale aiom giovani dritto e rovescio. 5/07/2024 – 06/07/2024 firenze (italy)
SUB INVESTIGATOR NEI SEGUENTI TRIAL CLINICI INTERNAZIONALI
- Phase II study Phase II study of Avelumab plus intermittent Axitinib in previously untreated patients with metastatic renal cell carcinoma (TIDE-A). Sub-investigator 2020 TIDE-A
- Phase III study A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE). Sub-investigator. 2023 NILE
- Phase III randomized study A Phase III, multicenter, randomized, open-label study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (The BURAN study). Sub-investigator 2023 BURAN
- Phase III randomized study A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle invasive Bladder Cancer (KEYNOTE-B15 / EV-304). Sub investigator. KEYNOTE-B15
- Phase III randomized study A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991). Sub-investigator. KEYNOTE-991
- Phase III randomized study An Open-label, Randomized, Phase 3 Study of MK 6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti PD-1/L1 Combination Regime (MK-6482 PN011). Sub-investigator. 2022 PN011
- Phase III randomized study A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676). Sub investigator. 2022 KEYNOTE 676
- Phase Ib/II study Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365). Sub-investigator. 2023 KEYNOTE- 365
- Phase II randomized study Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, multicenter study (Bonenza trial). Sub-investigator. 2022 Bonenza
- Phase III randomized study A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD L1 Expression (LEAP-011). Sub investigator. 2023 LEAP-011.